Market Overview:
The global metabolic disorders therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of metabolic disorders, rising awareness about available treatments, and technological advancements in the field of metabolic disorders therapeutics. The global metabolic disorders therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into metachromatic leukodystrophy (MLD), globoid leukodystrophy (GLD), hepatic encephalopathy (HE), and others. Region-wise, North America dominates this market followed by Europe and Asia Pacific respectively due to high prevalence rate for various types of metabolic disorder such as DM & obesity etc.
Product Definition:
Metabolic Disorders Therapeutics are a type of drug used to treat metabolic disorders. Metabolic disorders are diseases that affect the way the body uses food for energy. They can cause problems such as diabetes, obesity, and heart disease. Metabolic Disorders Therapeutics help to control these problems by regulating blood sugar levels and helping the body use food more efficiently.
Metachromatic Leukodystrophy:
Metachromatic Leukodystrophy (MLD) is a group of rare metabolic disorders characterized by the inability of the patient’s body to break down certain chemicals that are normally broken down into waste products. The most common symptom associated with this disease includes blue baby syndrome, which is caused due to an excess amount of metachromatic leukocytes in the infant’s blood.
Globoid Leukodystrophy:
Globoid Leukodystrophy (GLD) is a group of rare metabolic disorders characterized by the enlargement of leukocytes in the cerebrospinal fluid. Globoid leukodystrophy has three subtypes: infantile, early-onset, and late-onset.
Application Insights:
Diabetes is expected to be the fastest growing application segment over the forecast period owing to increasing prevalence of diabetes-related complications. For instance, according to data published by International Diabetes Federation in 2017, an estimated 1.3 billion people globally were affected by diabetes and this number is expected to reach about 2.0 billion by 2050 if current trends continue.
The other applications include hypoglycemic unawareness which is a condition characterized with severe hypoglycemia despite having normal blood glucose levels and adequate supplies of insulin or sugar-free insulin; ketoacidosis which is a life-threatening condition caused due largely to diabetic ketoacidosis; gout which occurs when there are high levels of uric acid in the body; rheumatoid arthritis that affects mostly children but also affects adults leading them into chronic pain.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers, suppliers, and research institutes involved in metabolic disorders therapeutics development is attributive for its dominance. Moreover, increasing prevalence of obesity and diabetes has also led to an increase in demand for these drugs over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income levels and improving healthcare infrastructure coupled with economic development within this region. Furthermore, growing awareness regarding various treatment options available along with increased R&D initiatives by major players are some factors that can be attributed towards regional growth over the next eight years (2018-2030).
Growth Factors:
- Increasing prevalence of metabolic disorders
- Growing awareness about the available treatment options for metabolic disorders
- Rising demand for better and more effective treatments for metabolic disorders
- Technological advancements in the field of metabolic disorder therapeutics
- Growing number of research and development activities focused on developing new and better therapies for metabolic disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabolic Disorders Therapeutics Market Research Report
By Type
Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, Others
By Application
Diabetes, Obesity, Hypercholesterolemia, Lysosomal Storage Diseases, Others
By Companies
AbbVie, Novo Nordisk, Actelion Pharmaceuticals, Sanofi, Biocon, Merck, Boehringer Ingelheim, AstraZeneca, CymaBay Therapeutics, Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Metabolic Disorders Therapeutics Market Report Segments:
The global Metabolic Disorders Therapeutics market is segmented on the basis of:
Types
Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetes, Obesity, Hypercholesterolemia, Lysosomal Storage Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Novo Nordisk
- Actelion Pharmaceuticals
- Sanofi
- Biocon
- Merck
- Boehringer Ingelheim
- AstraZeneca
- CymaBay Therapeutics
- Eli Lilly and Company
Highlights of The Metabolic Disorders Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Metachromatic Leukodystrophy
- Globoid Leukodystrophy
- Hepatic Encephalopathy
- Others
- By Application:
- Diabetes
- Obesity
- Hypercholesterolemia
- Lysosomal Storage Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabolic Disorders Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabolic disorders therapeutics is a sub-discipline of pharmacology that deals with the discovery, development and evaluation of new drugs for the treatment of metabolic diseases.
Some of the major companies in the metabolic disorders therapeutics market are AbbVie, Novo Nordisk, Actelion Pharmaceuticals, Sanofi, Biocon, Merck, Boehringer Ingelheim, AstraZeneca, CymaBay Therapeutics, Eli Lilly and Company.
The metabolic disorders therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metabolic Disorders Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metabolic Disorders Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metabolic Disorders Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metabolic Disorders Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metabolic Disorders Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Metabolic Disorders Therapeutics Market Size and Y-o-Y Growth
4.5.2 Metabolic Disorders Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Metabolic Disorders Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metabolic Disorders Therapeutics Market Size Forecast by Type
5.2.1 Metachromatic Leukodystrophy
5.2.2 Globoid Leukodystrophy
5.2.3 Hepatic Encephalopathy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metabolic Disorders Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metabolic Disorders Therapeutics Market Size Forecast by Applications
6.2.1 Diabetes
6.2.2 Obesity
6.2.3 Hypercholesterolemia
6.2.4 Lysosomal Storage Diseases
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metabolic Disorders Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metabolic Disorders Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metabolic Disorders Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Metabolic Disorders Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metabolic Disorders Therapeutics Market Size Forecast by Type
9.6.1 Metachromatic Leukodystrophy
9.6.2 Globoid Leukodystrophy
9.6.3 Hepatic Encephalopathy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metabolic Disorders Therapeutics Market Size Forecast by Applications
9.10.1 Diabetes
9.10.2 Obesity
9.10.3 Hypercholesterolemia
9.10.4 Lysosomal Storage Diseases
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metabolic Disorders Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Metabolic Disorders Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metabolic Disorders Therapeutics Market Size Forecast by Type
10.6.1 Metachromatic Leukodystrophy
10.6.2 Globoid Leukodystrophy
10.6.3 Hepatic Encephalopathy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metabolic Disorders Therapeutics Market Size Forecast by Applications
10.10.1 Diabetes
10.10.2 Obesity
10.10.3 Hypercholesterolemia
10.10.4 Lysosomal Storage Diseases
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metabolic Disorders Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metabolic Disorders Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metabolic Disorders Therapeutics Market Size Forecast by Type
11.6.1 Metachromatic Leukodystrophy
11.6.2 Globoid Leukodystrophy
11.6.3 Hepatic Encephalopathy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metabolic Disorders Therapeutics Market Size Forecast by Applications
11.10.1 Diabetes
11.10.2 Obesity
11.10.3 Hypercholesterolemia
11.10.4 Lysosomal Storage Diseases
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metabolic Disorders Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Metabolic Disorders Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metabolic Disorders Therapeutics Market Size Forecast by Type
12.6.1 Metachromatic Leukodystrophy
12.6.2 Globoid Leukodystrophy
12.6.3 Hepatic Encephalopathy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metabolic Disorders Therapeutics Market Size Forecast by Applications
12.10.1 Diabetes
12.10.2 Obesity
12.10.3 Hypercholesterolemia
12.10.4 Lysosomal Storage Diseases
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metabolic Disorders Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metabolic Disorders Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metabolic Disorders Therapeutics Market Size Forecast by Type
13.6.1 Metachromatic Leukodystrophy
13.6.2 Globoid Leukodystrophy
13.6.3 Hepatic Encephalopathy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metabolic Disorders Therapeutics Market Size Forecast by Applications
13.10.1 Diabetes
13.10.2 Obesity
13.10.3 Hypercholesterolemia
13.10.4 Lysosomal Storage Diseases
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metabolic Disorders Therapeutics Market: Competitive Dashboard
14.2 Global Metabolic Disorders Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Novo Nordisk
14.3.3 Actelion Pharmaceuticals
14.3.4 Sanofi
14.3.5 Biocon
14.3.6 Merck
14.3.7 Boehringer Ingelheim
14.3.8 AstraZeneca
14.3.9 CymaBay Therapeutics
14.3.10 Eli Lilly and Company
